- Home
- HQI vs CRDL Comparison
HQI vs CRDL Comparison
Compare HQI & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQI
- CRDL
- Stock Information
- Founded
- HQI 2002
- CRDL 2017
- Country
- HQI United States
- CRDL Canada
- Employees
- HQI N/A
- CRDL N/A
- Industry
- HQI Professional Services
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HQI Consumer Discretionary
- CRDL Health Care
- Exchange
- HQI Nasdaq
- CRDL Nasdaq
- Market Cap
- HQI 140.2M
- CRDL 126.5M
- IPO Year
- HQI N/A
- CRDL N/A
- Fundamental
- Price
- HQI $9.70
- CRDL $1.11
- Analyst Decision
- HQI Buy
- CRDL Strong Buy
- Analyst Count
- HQI 1
- CRDL 2
- Target Price
- HQI $13.00
- CRDL $9.00
- AVG Volume (30 Days)
- HQI 6.7K
- CRDL 706.5K
- Earning Date
- HQI 11-06-2025
- CRDL 11-13-2025
- Dividend Yield
- HQI 2.45%
- CRDL N/A
- EPS Growth
- HQI N/A
- CRDL N/A
- EPS
- HQI 0.17
- CRDL N/A
- Revenue
- HQI $32,610,000.00
- CRDL N/A
- Revenue This Year
- HQI N/A
- CRDL N/A
- Revenue Next Year
- HQI $1.38
- CRDL N/A
- P/E Ratio
- HQI $51.24
- CRDL N/A
- Revenue Growth
- HQI N/A
- CRDL N/A
- 52 Week Low
- HQI $8.94
- CRDL $0.77
- 52 Week High
- HQI $15.75
- CRDL $2.44
- Technical
- Relative Strength Index (RSI)
- HQI 48.27
- CRDL 47.34
- Support Level
- HQI $9.65
- CRDL $1.06
- Resistance Level
- HQI $10.07
- CRDL $1.10
- Average True Range (ATR)
- HQI 0.35
- CRDL 0.06
- MACD
- HQI 0.00
- CRDL 0.01
- Stochastic Oscillator
- HQI 39.76
- CRDL 50.29
About HQI HireQuest Inc. (DE)
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.